DK1962895T3 - TERAPEUTISK ANVENDELSE AF EN Dll4-ANTAGONIST OG EN VEGF-HÆMMER TIL HÆMNING AF TUMORVÆKST - Google Patents

TERAPEUTISK ANVENDELSE AF EN Dll4-ANTAGONIST OG EN VEGF-HÆMMER TIL HÆMNING AF TUMORVÆKST

Info

Publication number
DK1962895T3
DK1962895T3 DK06848586.1T DK06848586T DK1962895T3 DK 1962895 T3 DK1962895 T3 DK 1962895T3 DK 06848586 T DK06848586 T DK 06848586T DK 1962895 T3 DK1962895 T3 DK 1962895T3
Authority
DK
Denmark
Prior art keywords
tumor growth
therapeutic use
vegf inhibitor
dll4 antagonist
dll4
Prior art date
Application number
DK06848586.1T
Other languages
English (en)
Inventor
Irene Noguera
Gavin Thurston
Nicholas Gale
Eric Smith
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38163537&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1962895(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Application granted granted Critical
Publication of DK1962895T3 publication Critical patent/DK1962895T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK06848586.1T 2005-12-16 2006-12-15 TERAPEUTISK ANVENDELSE AF EN Dll4-ANTAGONIST OG EN VEGF-HÆMMER TIL HÆMNING AF TUMORVÆKST DK1962895T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US75117305P 2005-12-16 2005-12-16
US77127606P 2006-02-08 2006-02-08
US78845606P 2006-03-31 2006-03-31
US83054306P 2006-07-12 2006-07-12
PCT/US2006/047848 WO2007070671A2 (en) 2005-12-16 2006-12-15 Therapeutic methods for inhibiting tumor growth with dll4 antagonists

Publications (1)

Publication Number Publication Date
DK1962895T3 true DK1962895T3 (da) 2013-03-04

Family

ID=38163537

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06848586.1T DK1962895T3 (da) 2005-12-16 2006-12-15 TERAPEUTISK ANVENDELSE AF EN Dll4-ANTAGONIST OG EN VEGF-HÆMMER TIL HÆMNING AF TUMORVÆKST

Country Status (12)

Country Link
US (1) US20080107648A1 (da)
EP (1) EP1962895B2 (da)
JP (1) JP5489465B2 (da)
AU (1) AU2006326417B2 (da)
CA (1) CA2630839C (da)
DK (1) DK1962895T3 (da)
ES (1) ES2400666T5 (da)
IL (1) IL191810A (da)
NZ (1) NZ568739A (da)
PL (1) PL1962895T3 (da)
PT (1) PT1962895E (da)
WO (1) WO2007070671A2 (da)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6984522B2 (en) * 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US7906116B2 (en) 2005-09-01 2011-03-15 Parkash Gill Methods for using and identifying modulators of Delta-like 4
JP2009539870A (ja) * 2006-06-06 2009-11-19 ジェネンテック・インコーポレーテッド 血管発生の調節ための組成物および方法
AU2007319672B2 (en) * 2006-06-06 2011-06-30 Genentech, Inc. Anti-DLL4 antibodies and methods using same
HRP20160082T1 (hr) * 2006-09-29 2016-02-26 Oncomed Pharmaceuticals, Inc. Sastavi i postupci za dijagnosticiranje i lijeäśenje raka
EP2081962B1 (en) 2006-10-19 2018-10-03 Genentech, Inc. Novel anti-notch3 antibodies and their use in the detection and diagnosis of disease
JP5478254B2 (ja) 2006-10-19 2014-04-23 ジェネンテック， インコーポレイテッド 抗ノッチ３アゴニスト抗体とノッチ３関連疾患の治療におけるその使用
RU2448979C2 (ru) * 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
EP2099827B1 (en) 2006-12-18 2018-11-21 Genentech, Inc. Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases
EP2120996A2 (en) * 2006-12-20 2009-11-25 Vasgene Therapeutics, Inc. Methods for using and identifying modulators of delta-like 4
EP2106439B1 (en) 2007-01-24 2014-11-12 The Regents of the University of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
EP2125013A4 (en) * 2007-01-26 2010-04-07 Bioinvent Int Ab DLL4 SIGNALING INHIBITOR AND ITS USES
GB0709333D0 (en) * 2007-05-15 2007-06-20 Smart Targeting Ltd Binding protein
PE20090321A1 (es) 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
US8557965B2 (en) 2008-04-07 2013-10-15 Ablynx N.V. Single variable domains against notch pathway members
CN102112490B (zh) 2008-07-08 2014-10-22 昂考梅德药品有限公司 Notch1受体结合剂和其使用方法
US7544476B1 (en) * 2008-07-11 2009-06-09 Aveo Pharmaceuticals, Inc. Identifying cancers sensitive to treatment with inhibitors of notch signaling
CN102264763B (zh) * 2008-09-19 2016-04-27 米迪缪尼有限公司 定向于dll4的抗体及其用途
MX2011002928A (es) * 2008-10-01 2011-04-11 Genentech Inc Anticuerpos anti-notch2 y metodos de uso.
US9221902B2 (en) 2008-11-07 2015-12-29 Fabrus, Inc. Combinatorial antibody libraries and uses thereof
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
TWI513465B (zh) * 2009-06-25 2015-12-21 Regeneron Pharma 以ｄｌｌ４拮抗劑與化學治療劑治療癌症之方法
CA2771575A1 (en) * 2009-08-29 2011-03-03 Abbott Laboratories Therapeutic dll4 binding proteins
UY32920A (es) 2009-10-02 2011-04-29 Boehringer Ingelheim Int Moleculas de unión biespecíficas para la terapia anti-angiogénesis
UY32917A (es) * 2009-10-02 2011-04-29 Boehringer Ingelheim Int Moléculas de unión a dll-4
EP3485908B1 (en) 2009-10-16 2021-08-18 Mereo BioPharma 5, Inc. Therapeutic combination and use of dll4 antagonist antibodies and anti-hypertensive agents
US20110165162A1 (en) * 2009-12-01 2011-07-07 Oncomed Pharmaceuticals, Inc. Methods for Treating Cancers Comprising K-ras Mutations
JO3274B1 (ar) 2009-12-24 2018-09-16 Regeneron Pharma أجسام مضادة بشرية للبروتين 4 المشابه لأجيوبيوتين البشري
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
MX2012008085A (es) 2010-01-13 2012-09-12 Oncomed Pharm Inc Agentes de union notch1 y metodos de uso de los mismos.
JO3183B1 (ar) 2010-01-29 2018-03-08 Regeneron Pharma طرق لمعالجة أمراض المناعة الذاتية مضادات dll4
WO2011109298A2 (en) 2010-03-02 2011-09-09 Abbott Laboratories Therapeutic dll4 binding proteins
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
US20130078247A1 (en) * 2011-04-01 2013-03-28 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to dii4 and ang2
AR087329A1 (es) 2011-06-17 2014-03-19 Regeneron Pharma Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana
TWI583699B (zh) 2011-09-23 2017-05-21 安可美德藥物股份有限公司 Ｖｅｇｆ／ｄｌｌ４結合劑類及彼等之用途
US20140093498A1 (en) 2012-09-28 2014-04-03 Boehringer Ingelheim International Gmbh Pharmaceutical combinations comprising dual angiopoietin-2 / dll4 binders and anti-vegf-r agents
CA2889638A1 (en) 2012-10-31 2014-05-08 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a dll4 antagonist
TW201438736A (zh) 2012-11-14 2014-10-16 Regeneron Pharma 以ｄｌｌ４拮抗劑治療卵巢癌之方法
EP3212233B1 (en) 2014-10-31 2020-06-24 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
US11339213B2 (en) 2015-09-23 2022-05-24 Mereo Biopharma 5, Inc. Methods and compositions for treatment of cancer
US11524053B2 (en) 2018-01-26 2022-12-13 The Regents Of The University Of California Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents
CN114867487A (zh) 2019-11-25 2022-08-05 加利福尼亚大学董事会 用于眼内新生血管的长效vegf抑制剂
WO2023063842A1 (ru) * 2021-10-12 2023-04-20 Общество с ограниченной ответственностью "Пальмира Биофарма" Нуклеотидная последовательность, кодирующая слитый белок
WO2024130165A1 (en) 2022-12-16 2024-06-20 Regeneron Pharmaceuticals, Inc. Angptl3 inhibitors for triglyceride reduction in multifactorial chylomicronemia syndrome

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6121045A (en) * 1997-04-04 2000-09-19 Millennium Biotherapeutics, Inc. Human Delta3 nucleic acid molecules
DE69829891T2 (de) † 1997-04-07 2005-10-06 Genentech, Inc., South San Francisco Anti-VEGF Antikörper
JP4171528B2 (ja) * 1997-05-14 2008-10-22 旭化成株式会社 新規な分化抑制剤
EP1179541B1 (en) † 1999-04-28 2004-06-16 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting VEGF
US7087411B2 (en) * 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
CN101433715B (zh) † 1999-06-08 2013-04-17 里珍纳龙药品有限公司 具有改善的药物动力学特性的修饰嵌合多肽
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US6984522B2 (en) * 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US20050089518A1 (en) * 2001-12-07 2005-04-28 Clarke Michael F. Prospective identification and characterization of breast cancer stem cells
JP2005526701A (ja) * 2001-11-14 2005-09-08 ロランティス リミテッド 内科療法
EP1537145A1 (en) 2002-09-10 2005-06-08 Lorantis Limited Pharmaceutical compositions and medical treatments comprising notch ligand proteins
US20060134121A1 (en) 2004-10-29 2006-06-22 Gavin Thurston DII4 antagonists, assays, and therapeutic methods thereof
EP1928486A2 (en) * 2005-09-01 2008-06-11 Vasgene Therapeutics, Inc. Methods for using and identifying modulators of delta-like 4
JP2009539870A (ja) * 2006-06-06 2009-11-19 ジェネンテック・インコーポレーテッド 血管発生の調節ための組成物および方法
AU2007319672B2 (en) † 2006-06-06 2011-06-30 Genentech, Inc. Anti-DLL4 antibodies and methods using same

Also Published As

Publication number Publication date
AU2006326417B2 (en) 2012-05-24
WO2007070671A3 (en) 2008-01-10
PL1962895T3 (pl) 2013-06-28
JP2009519944A (ja) 2009-05-21
PT1962895E (pt) 2013-03-28
IL191810A0 (en) 2009-02-11
NZ568739A (en) 2010-09-30
CA2630839A1 (en) 2007-06-21
IL191810A (en) 2017-11-30
CA2630839C (en) 2017-01-17
EP1962895A2 (en) 2008-09-03
AU2006326417A1 (en) 2007-06-21
EP1962895B2 (en) 2016-01-20
EP1962895B1 (en) 2013-02-13
US20080107648A1 (en) 2008-05-08
WO2007070671A2 (en) 2007-06-21
ES2400666T3 (es) 2013-04-11
JP5489465B2 (ja) 2014-05-14
ES2400666T5 (es) 2016-03-10

Similar Documents

Publication Publication Date Title
LTC1761540I2 (lt) Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės-delta inhibitoriai
PT1962895E (pt) Utilização terapêutica de um antagonista dll4 e de um inibidor fcev para inibição de crescimento de tumores
DK1913157T3 (da) EGFR og KRAS mutationer til forudsigelse af patientrespons for EGFR inhibitorbehandling
DK1802872T3 (da) Rörledning
DK2099796T3 (da) Aza-indolyl-forbindelser og fremgangsmåder for anvendelse
CY2014011I2 (el) Χορηγηση αναστολεων διπεπτιδυλοπεπτιδασης
DK1753748T3 (da) Prolinderivater og deres anvendelse som dipeptidyl-peptidase-IV-inhibitorer
CY2013042I1 (el) Αναστολεις πυριδυλιου της σηματοδοτησης hedgehog
DK2185164T3 (da) Sammensætning og terapeutisk antitumorvaccine
DK2379096T3 (da) TFPI-inhibitorer og fremgangsmåder til anvendelse
DK2073811T3 (da) Kinaseinhibitorer anvendelige til behandling af myeloproliferative sygdomme og andre proliferative sygdomme
IS8597A (is) Samsetningar rísedrónats og aðferðir við notkun þess
HUS1400007I1 (hu) Dipeptidil-peptidáz inhibitorok
DK2041129T3 (da) Inhibitorer af human proteintyrosinphosphatase og deres farmaceutiske anvendelse
DK1940839T3 (da) Pyridopyrimidione Inhibitors of P13Ka
DK1815247T3 (da) Terapeutisk anvendelse af farnesyltransferaseinhibitorer og fremgangsmåder til overvågning af deres effektivitet
DK1771446T3 (da) Azaindolinhibitorer af MTP og APOB
DE602005023266D1 (de) Azabenzofuransubstituierte thioharnstoffe als inhibitoren der virusreplikation
DK2059246T3 (da) Terapeutiske sammensætninger omfattende en specifik endothelin-receptorantagonist og en PDE5-inhibitor
DK2001556T3 (da) Thioninium-forbindelser og anvendelse deraf
DE602005019971D1 (de) Inhibitoren von cysteinprotease
DK2069467T3 (da) Adskillende sammensætninger og fremgangsmåder til anvendelse
ITMI20041869A1 (it) Nuovi inibitori delle istone deacetilasi
DK1928457T3 (da) Quinoliner og deres terapeutiske anvendelse
DK3309233T4 (da) Sammensætninger omfattende hfc-1234yf og hfc-152a